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INTRODUCTION
Retinitis pigmentosa (RP), the most frequently inherited reti-
nal dystrophy (iRD), is characterized by tremendous genetic 
heterogeneity, with mutations in more than 70 genes explain-
ing 30 to 80% of cases, depending on the mode of inheritance.1 
Although RP is clinically distinct from other iRDs, end-stage 
RP may be difficult to differentiate from late stages of some 
cone–rod dystrophies (CRD) and macular dystrophies (MDs).
To date, targeted next-generation sequencing (NGS) of gene 
panels and whole-exome sequencing (WES) are commonly 
used approaches to establish a molecular diagnosis of RP. These 
sequencing techniques are aimed mainly at identifying single-
nucleotide variants and small insertions and deletions in cod-
ing sequences of known and candidate genes, but they are less 
suitable for finding coding or noncoding copy number varia-
tions (CNVs). Although a higher prevalence of CNVs has been 
described in a limited number of iRD genes such as PRPF31,2 
EYS,3,4 KCNV2,5 and USH2A,3,4,6 CNV analysis is not systemati-
cally included in the genetic workup of iRD, probably leading to 
an underestimation of CNVs as a cause of iRD. Indeed, Khateb 
et al. recently identified subtle single-exon to multigene dele-
tions involving EYS, MYO7A, NPHP4, RPGR, and CHM in 10% 
of a cohort of 60 iRD cases using WES data, emphasizing the 
importance of CNV screening in iRD.7 
CNV analysis in iRD using WES, targeted NGS, and 
whole-genome sequencing (WGS) data has been proven to 
be increasingly successful.3,4,7–9 Because exons are unevenly 
distributed within the genome, algorithms using read depth 
are recommended for CNV analysis using WES and tar-
geted NGS data. Despite the development of different CNV 
tools over the past years, none has the same performance 
of microarray-based comparative genomic hybridization 
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Purpose: Our goal was to design a customized microarray, arrEYE, 
for high-resolution copy number variant (CNV) analysis of known 
and candidate genes for inherited retinal dystrophy (iRD) and retina-
expressed noncoding RNAs (ncRNAs).
Methods: arrEYE contains probes for the full genomic region of 106 
known iRD genes, including those implicated in retinitis pigmentosa 
(RP) (the most frequent iRD), cone–rod dystrophies, macular dys-
trophies, and an additional 60 candidate iRD genes and 196 ncRNAs. 
Eight CNVs in iRD genes identified by other techniques were used as 
positive controls. The test cohort consisted of 57 patients with auto-
somal dominant, X-linked, or simplex RP.
Results: In an RP patient, a novel heterozygous deletion of exons 
7 and 8 of the HGSNAT gene was identified: c.634-408_820+338delins 
AGAATATG, p.(Glu212Glyfs*2). A known variant was found on the 
second allele: c.1843G>A, p.(Ala615Thr). Furthermore, we expanded the 
allelic spectrum of USH2A and RCBTB1 with novel CNVs.
Conclusion: The arrEYE platform revealed subtle single-exon to 
larger CNVs in iRD genes that could be characterized at the nucleo-
tide level, facilitated by the high resolution of the platform. We report 
the first CNV in HGSNAT that, combined with another mutation, 
leads to RP, further supporting its recently identified role in nonsyn-
dromic iRD.
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(array CGH). The WES CNV analyses have variable perfor-
mance, with a high false-positive rate, low sensitivity, and a 
duplication bias. To avoid a high false-positive rate, high-
coverage data are required.7,10 By improving the design of 
targeted NGS approaches, high- coverage NGS data can be 
easily obtained.4,8,11 Despite higher sensitivity and specificity 
of recent tools, additional validation of identified CNVs and 
low-quality targets are still recommended to avoid false-pos-
itive and false-negative results, respectively.12 WGS is more 
reliable than WES for CNV assessment because it covers the 
breakpoint junctions that mostly reside in intronic regions, 
thus facilitating the detection of more complex CNVs, and 
because it performs with a greater uniform distribution of 
sequencing-quality parameters.3 Obtaining high-coverage 
data is a prerequisite for accurate CNV analysis using WGS, 
thus increasing its costs. A combined approach of NGS and 
array CGH allows identification of a wide range of mutations 
for heterogeneous diseases such as iRD and allows for over-
coming the aforementioned issues.
Here, we developed a customized array CGH platform, called 
arrEYE, for copy-number analysis of coding and noncoding 
regions of known and candidate RP, CRD, and MD genes and of 
retina-expressed noncoding RNAs (ncRNAs) such as micro RNAs 
(miRNAs) and long intergenic noncoding RNAs (lincRNAs). 
The arrEYE chip was validated using seven positive control 
samples with eight CNVs in known RP genes, which had been 
identified using other techniques. Next, 57 prescreened index 
cases with RP underwent CNV analysis using arrEYE. We 
discuss the identification of three novel CNVs in iRD genes, 
including HGSNAT, which was recently associated with non-
syndromic iRD, USH2A, and RCBTB1, a recently discovered 
novel iRD gene. We demonstrate that arrEYE allows detection 
of subtle single-exon to larger CNVs in known and candidate 
iRD genes and that novel identified CNVs could be easily char-
acterized at the nucleotide level, thus allowing unraveling of 
their underlying mechanisms.
MATERIALs AND METHODs
Ethics statement
This study was conducted following the tenets of the Declaration 
of Helsinki.
Patient samples
We studied 57 patients (P1 to P57) initially diagnosed with auto-
somal dominant (n=39), X-linked (n = 3), or simplex (n = 15) 
RP and referred for molecular genetic testing by either oph-
thalmologists or clinical geneticists. Genomic DNA (gDNA) 
was extracted from leukocytes using the QIAamp DNA mini 
kit (Qiagen, Antwerp, Belgium), the Gentra Puregene Cell kit 
(Qiagen, Antwerp, Belgium), or the ReliaPrep Large-Volume 
HT gDNA Isolation System (Promega, Leiden, Netherlands) 
according to the manufacturer’s descriptions. Most patients 
previously underwent adRP APEX chip analysis (Asper 
Ophthalmics, Tartu, Estonia). All patients were tested for 
mutations in coding exons and intron–exon boundaries of the 
four most prevalent adRP genes (RHO, RP1, PRPH2, PRPF31).
Seven positive controls were included (PC1 to PC7), with 
eight CNVs in one of the genes present on the customized 
array, hereafter called arrEYE.
Microarray probe design
We used the Agilent oligonucleotide-based microarray tech-
nology and the SurePrint 8 × 60K format. The arrEYE micro-
array design was developed using the Web-based application 
SureDesign (https://earray.chem.agilent.com/suredesign/; 
Agilent Technologies, Santa Clare, CA). We created five differ-
ent probe groups, each containing a specific set of genes and 
miRNAs or lincRNAs. The Agilent High-Definition Database 
(July 2015, human reference sequence, hg19, Build GRCh37, 
February 2009) was used to select probes. More detailed infor-
mation is available in the Supplementary data (Supplementary 
Table S1 online).
Microarray-based comparative genomic hybridization 
(array CGH) and data analysis
In brief, 200 ng of genomic DNA was labeled using the 
BioPrime Array CGH Genomic Labeling Module (Invitrogen, 
Merelbeke, Belgium) using cyanine 5 (Cy5)-labeled (control 
gDNA; Promega) and cyanine 3 (Cy3)-labeled (patient gDNA) 
deoxycytidine triphosphate (dCTPs; GE Healthcare, Diegem, 
Belgium). Following precipitation, hybridization with Cot-1 
DNA, and washing, the array slides were scanned using an 
Agilent DNA Microarray Scanner and quantified with Agilent 
Feature Extraction Software (version 10.7.1.1). The data were 
further processed, analyzed, and visualized using the ViVar 
platform13 (October 2015; https://www.cmgg.be/vivar/) using 
a circular binary segmentation algorithm. Prior to the valida-
tion, we considered a region deleted or duplicated when the 
log2 ratio encompassing at least three probes was below −0.35 
or above +0.35, respectively. The derivative log ratio (DLR), 
which calculated the probe-to-probe log ratio noise, was used 
as a quality parameter. Typically, a DLR spread of 0.20 is con-
sidered a threshold for detecting small aberrations. A DLR 
≤0.19 is accepted as good array quality, a DLR between 0.20 
and 0.29 is considered borderline, and a DLR ≥0.30 should be 
rejected.14
qPCR validation of CNVs
CNVs found in the patient samples were confirmed using qPCR 
(LightCycler 480; Roche, Vilvoorde, Belgium; data analysis: 
qbase+ 3.0, Biogazelle, Zwijnaarde, Belgium; Supplementary 
Table S2 online). The genomic positions of the CNVs found 
by array CGH were used to design primers for junction PCR 
and breakpoint sequencing. qPCR primers were designed using 
PrimerQuest (http://eu.idtdna.com/primerquest/home/index) 
and PrimerXL (http://www.primerxl.org). Junction primers 
were designed using Primer3Plus (http://www.bioinformatics.
nl/cgi-bin/primer3plus/primer3plus.cgi).
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CNV and variant interpretation
Several databases were used to interpret the pathogenic signifi-
cance of identified CNVs. The Database of Genomic Variants 
(http://www.ncbi.tcag.ca/varation) continuously updates CNVs 
found in healthy controls. The Database of Chromosomal 
Imbalance and Phenotype in Humans using Ensembl Resources 
(DECIPHER; https://decipher.sanger.ac.uk/) catalogs clinically 
relevant CNVs. In addition, genetic disorders caused by CNVs 
are cataloged in the Online Mendelian Inheritance in Man 
(OMIM; http://www.cnbi.nlm.nih.gov/omim) database.
The functional impact of sequence variants was assessed 
based on the outcome of in silico predictions performed in 
Alamut 2.7 (Interactive Biosoftware, Rouen, France).
PCR and sanger sequencing
All exons and exon–intron boundaries of the RCBTB1, 
HGSNAT, and USH2A genes were PCR-enriched and Sanger-
sequenced in P4, P33, and P53, respectively. Primers were 
designed (Supplementary Table S3 online) using the online 
primer design software tools Primer3Plus (http://www.bioin-
formatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and pxlence 
(https://pxlence.com).
REsULTs
Customized microarray probe design
Details about the genes, number of probes, and the median 
probe spacing are provided in Supplementary Table S1 online.
The first probe group included 109 genes known to cause 
autosomal dominant, recessive, or X-linked RP, CRD, or MD: 
genes listed in RetNet (https://sph.uth.edu/retnet) (n = 106) 
and three candidate genes.
The second probe group was based on a data set generated 
by cone–rod homeobox (CRX) chromatin immunoprecipita-
tion with massively parallel sequencing (ChIP-seq) in adult 
mouse retina. CRX is a key transcription factor for photore-
ceptor differentiation and survival that regulates downstream 
Figure 1  Array CGH profiles of copy number variations in positive controls. E: exon. Crossed dots indicate probes with a ratio outside the shown 
y-axis, with no further impact on the calculations. (a) Positive control 1. A heterozygous duplication of exon 4 to exon 13 in USH2A. (b) Positive control 2. 
A heterozygous deletion of exon 44 in USH2A. (c) Positive control 3. A heterozygous deletion of exons 22 to 24 in USH2A. (d) Positive control 4. A heterozygous 
deletion of exon 1 and exon 2 in BEST1. (e) Positive control 5. A compound heterozygous deletion of exon 2 in KCNV2.
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photoreceptor transcription factors and their target genes. 
The CRX ChIP-seq data set provided a map of cis-regulatory 
CRX-binding regions (CBRs) clustering around photoreceptor 
genes.15 By combining the CBR data with the genomic positions 
of published RP candidate (RP6, RP22, RP24, RP29, RP32, 
RP34, RP63), a total of 36 candidate genes were included.
The third probe group contained genes that are directly con-
nected to seven splicing factor genes that have previously been 
implicated in adRP (RetNet). Six of these encoded proteins of the 
tri-small nuclear ribonucleoprotein (tri-snRNP) complex. Gene 
selection was first based on the work by Benaglio et al.,16 in which 
four tri-snRNP splicing factor genes (EFTUD2, AAR2, NHP2L1, 
and PRPF4) were screened in adRP cases. Furthermore, spli-
ceosomal proteins shown to interact with proteins previously 
implicated in adRP were included.17 Finally, CNOT3, known 
to modulate the effect of PRPF31 mutations, was included.18 
Overall, probe group 3 contained 21 candidate genes.
The fourth probe group was composed of miRNAs poten-
tially regulating gene expression in the eye. First, 220 miRNAs 
from miRNeye, a high-resolution expression atlas of miRNAs 
Figure 2 Heterozygous deletion encompassing exons 7 and 8 of HGSNAT. (a) From the top down: composite fundus pictures; infrared reflectance 
composites and optical coherence tomography (OCT) of right eye; and blue light fundus autofluorescence (BAF) image of left eye of patient P33. LE: left eye, 
RE: right eye. The fundoscopy shows typical signs of RP, with outer retinal atrophy and mostly spicular but some nummular intraretinal pigmentation in the 
midperiphery, with better preservation of retina in the far periphery and pericentral macula. Infrared reflectance composite fundus images of patient P33 
(HRA2; Heidelberg, Germany) illustrates these signs further. OCT of the central macula shows severe atrophy of outer retinal layers representing retinal pigment 
epithelium and photoreceptors, with some remnants remaining in immediate perifoveal area and extreme thinning of fovea. On BAF image of the LE, severe 
outer retinal atrophy in the posterior pole with hyperautofluorescent ring, which is surrounded by a ring of outer retinal atrophy with highly visible, fibrotic, 
larger choroidal vessels; around that, another concentric area of hypoautofluorescence is coincident with an area of intraretinal pigmentation. (b) Segregation 
analysis of the identified deletion and unclassified variant c.1843G>A p.(Ala615Thr). III:1: proband patient P33. (c) Array CGH profile. E: exon. (d) qPCR plot. 
Exons 6 and 9 have a normal copy number (gray bars), whereas exons 7 and 8 have only 1 copy (reddish bars). E: exon. (e) Schematic representation of the 
HGSNAT deletion. From the top down: localization of the deletion relative to the entire HGSNAT gene; zoomed to the level of exons 7 and 8; breakpoint 
regions; and sequence level of the junction. The nucleotides of the breakpoint regions are indicated with a gray and pink bar. Eight nucleotides (AGAATATG) 
are inserted in between. Red bar: deletion; blue bar: coding region; blue line: intronic region.
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expressed in the developing and adult wild-type mouse eye, 
were included.19 Second, literature-based selection of miRNAs 
associated with iRD (e.g., miR-204),20 miRNAs with a differ-
ential retinal expression in RP mouse models (e.g., miR-96),21 
and miRNAs expressed in human retina (e.g., miR-124)22 
resulted in 27 additional miRNAs. The miRBase Tracker 
(http://www.mirbasetracker.org) was used to map the miRNA 
names to the most recent miRBase accession number. Human 
homologs were selected by performing a very stringent BLAST 
alignment (e-value <0.02) of the miRNA sequences to all 
human miRNAs in miRBase (See R code in Supplementary 
File S1 online).23
The fifth probe group contained evolutionarily conserved 
lincRNAs expressed in retinal tissues.24
Validation of the customized microarray
Validation of previously identified CNVs. Samples were 
included from seven patients (PC1-7) with eight CNVs identified 
using either MLPA (heterozygous CNVs) or nonamplification 
with conventional PCR (homozygous CNVs).25 Of these eight 
CNVs, seven were detected using arrEYE. The first CNV (PC1; 
Figure 1a, Table 1), a heterozygous duplication encompassing 
exon 4 to exon 13 of the USH2A gene, showed a change of 
443 probes (ratio: 0.5325), thus confirming this duplication. 
The second CNV (PC2; Figure 1b, Table 1), a heterozygous 
deletion of USH2A exon 44, showed decreased signals for six 
probes covering exon 44 and its intron–exon boundaries (ratio: 
−0.5614). The deletion had previously been delineated by 
qPCR and Sanger sequencing of the junction product (chr1:g.
(216040210_216042178)del). Using the arrEYE chip, we were 
able to approximately define the breakpoint boundaries (chr1:g.
(216039973_216040269)_(216041753_216042428)del). A third 
CNV, a heterozygous deletion of exons 22–24 of USH2A (PC3; 
Figure 1c, Table 1), displayed lower signals for 201 probes 
(ratio: −0.52), thus confirming this heterozygous deletion. The 
fourth CNV (PC4, Figure 1d, Table 1), a heterozygous BEST1 
deletion of exons 1 and 2, showed decreased signals for 15 
probes encompassing these exons (ratio: −0.5393). The fifth and 
sixth CNVs, which were two distinct, compound, heterozygous 
deletions both encompassing the last exon (exon 2) of KCNV2 
(PC5; Figure 1e, Table 1), were identified as a homozygous 
deletion by a decreased signal of 20 probes (ratio: −1.31). The 
sixth and seventh positive control samples performed with a poor 
DLR spread (DLR > 0.20), thereby hampering an accurate CNV 
analysis. The seventh CNV, a homozygous SPATA7 deletion of 
exons 1–4 (PC6; DLR = 0.2166), showed absent signals for 86 
probes (probes dropped to a ratio of −1.26), thereby confirming 
the homozygous deletion (Supplementary Figure S1 online, 
Table 1). An eighth CNV, a heterozygous deletion of ABCA4 
exons 20–22 (PC7; DLR = 0.4233), could not be detected due to 
the spread of the probes as a result of poor DNA quality.
Defining the diagnostic thresholds. To assess the DLR 
cut-off of our arrEYE platform, a total of 36 exonic putative 
CNVs found in our RP test cohort (regardless of the DLR 
value and the number of altered probes) were validated using 
qPCR (Supplementary Tables S2 and S4 online). Of these, 
three CNVs could be validated as true CNVs. For each CNV, 
including the seven validated CNVs of the positive control 
samples, the number of altered probes was plotted against the 
DLR ratio of the sample (42 CNVs in total; Supplementary 
Figure S2 online; Supplementary Table S4 online). A clear-
cut threshold of 0.1467 for the DLR ratio and a threshold 
of more than five altered probes are needed to obtain an 
accurate result. One CNV, however, met the aforementioned 
threshold values (P51; DLR: 0.1199; 24 probes) but could not 
Table 2 Identified sequence variations and in silico predictions
Patient ID P33 P4
Chromosome 8 13
Gene HGSNAT RCBTB1
Exon 18 6
gDNA level (GRCh37/hg19) g.43054647G>A g.50129660G>C
Reference sequence NM_152419.2 NM_018191.3
cDNA level c.1843G>A c.594C>G
Protein level p.(Ala615Thr) p.(Asp198Glu)
Mutation type Missense substitution Missense substitution
Align GVGD C0 C0
SIFT Tolerated Deleterious
Polyphen-2 (HumVar) Benign (0.195; Sensitivity: 0.88; Specificity: 0.73) Benign (0.020; sensitivity: 0.95; specificity: 0.56)
Mutation taster Disease-causing Disease-causing
Grantham score 58 45
Nucleotide conservation High (phyloP: 5.05 [-14.1;6.4]) Moderate (phyloP:2.38 [-14.1;6.4])
Amino acid conservation High (up to Tetraodon) High (up to Tetraodon)
Splicing effects No change No change
Exome Aggregation Consortium MAF All: A = 0.44% MAF All: G = 0.17%
cDNA, complementary DNA; gDNA, genomic DNA; MAF, minor allele frequency; SIFT, “Sorting Intolerant from Tolerant” algorithm.
 Volume 19  |  Number 4  |  April 2017  |  GENETICs in MEDICINE
463
A copy number analysis platform for retinal dystrophy genes and ncRNAs   |  VAN CAUWENBERGH et al Original research article
be validated using qPCR. To explain this outlier, we must 
take into account the dynamic range of the log2 ratio, which 
is another important parameter to evaluate the microarray 
experiment. A deletion gives a theoretical log2 ratio of −1 
(log2 1/2), whereas a duplication gives a theoretical log2 ratio 
of 0.58 (log2 3/2). In practice, these values have a dynamic 
range due to nonspecific hybridization, autofluorescence, 
washing conditions, and background noise. The upper 
threshold for duplication was set at 0.35 and that for 
deletions was set at −0.35. The ratio value of this specific 
deletion is −0.36, which is close to the lower threshold set. All 
heterozygous deletions detected using the arrEYE platform 
reach a ratio value between −0.51 and −0.81 (Table 1). To 
exclude false-positive results, the lower threshold was set to 
at least −0.37 (but preferably −0.50).
Identification of CNVs in three probands with iRD
Heterozygous exons 7 and 8 deletion in novel iRD gene 
HGSNAT. Array CGH revealed a heterozygous 2.5-kb deletion of 
exons 7 and 8 of the HGSNAT gene in a male patient (P33) with 
sporadic RP (Figure 2). The deletion was confirmed by qPCR 
in both the male patient and his clinically unaffected daughter. 
Using primers flanking the altered probes, the breakpoints of 
the deletion could be determined at the nucleotide level: c.634-
408_820+338delinsAGAATATG (chr8:43,025,320_43,027,867
delinsAGAATATG) (Table 1, Figure 2e). This deletion creates 
a frameshift p.(Glu212Glyfs*2) that might be targeted by 
nonsense-mediated decay. Except for two deletions (spanning 
more than 1 Mb), no other overlapping structural variations 
were reported in any of the investigated databases. Sanger 
sequencing of the HGSNAT gene revealed missense variant 
c.1843G>A, p.(Ala615Thr) in exon 18. The alanine residue is 
highly conserved, but the change is predicted as tolerated by 
several in silico analyses. The variant represents a known SNP 
(rs112029032) with an overall minor allele frequency of 0.44% 
(ExAC) (Table 2). However, this missense variant has recently 
been described in a homozygous state in three Dutch siblings 
with nonsyndromic RP with just one of the two alleles in cis 
with the missense variant c.398G>C p.(Gly133Ala) (MIM 
616544).26 In addition, the p.(Ala615Thr) variant has also been 
reported in patients with mucopolysaccharidosis type IIIC 
(MPS IIIC, MIM 252930); in this case, it was in cis with either 
a splice site mutation or a missense mutation.27 Segregation 
analysis showed that the deletion found here and p.(Ala615Thr) 
are located in trans (Figure 2b). The patient (P33) had late-
onset RP with initial night blindness since age 47 years and slow 
Figure 3 Heterozygous deletion encompassing exons 42 to 44 of USH2A. (a) Array CGH profile. E: exon. (b) qPCR plot proband (P53). Exons 41 and 45 have 
a normal copy number (gray bars), whereas exon 42 to 44 have only one copy (reddish bars). (c) Segregation analysis of the identified deletion. II:4: proband patient 
P53. (d) Schematic representation of the USH2A deletion. From the top down: localization of the deletion relative to the entire USH2A gene; zoomed to the level 
of exon 42 to 44; breakpoint regions; and sequence level of the junction. The nucleotides of the breakpoint regions are indicated with a gray and pink bar. The two 
nucleotides (GT) with microhomology at the breakpoints are indicated with a turquoise bar. Red bar: deletion; blue bar: coding region; blue line: intronic region.
a
d
b c
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disease progression. A characteristic hyperautofluorescent ring 
surrounding the central macula, midperipheral outer retinal 
atrophy with intraretinal pigmentation of mixed specular and 
nummular types, and attenuated retinal vasculature were seen 
(Figure 2a). No systemic disease manifestations were recorded.
Novel heterozygous deletion in USH2A. In a patient (P53) 
with late-onset RP, a heterozygous 24-kb deletion of exons 42 
to 44 of the USH2A gene was found (Figure 3). Sequencing 
of the breakpoint junction fragment revealed the exact 
position of the breakpoints: c.8223+4491_8845+6927del 
(chr1:216033422_216057277del) p.Val2742Leufs*25 (Table 1, 
Figure 3d). No overlapping deletions were reported in any of 
the investigated databases. The USH2A gene is known to cause 
Usher syndrome, an autosomal recessive disorder characterized 
by mild to severe hearing impairment and RP (MIM 276901). 
The USH2A gene has been associated with nonsyndromic RP 
(MIM 613809).28 Targeted resequencing of USH2A and of a deep 
intronic region covering the location of a known pathogenic 
deep intronic mutation (c.7595-2144A>G)29 did not reveal a 
second mutation. Although other deep intronic and regulatory 
mutations cannot be excluded, a mutation in another gene may 
underlie the phenotype because both the father and the brother 
of the patient presented with iRD, which is rather compatible 
with autosomal dominant inheritance (Figure 3c).
Heterozygous duplication in novel iRD gene RCBTB1. A 
heterozygous duplication containing the first nine exons of 
RCBTB1 was identified in a patient (P4) with RP but with 
chorioretinal atrophy more pronounced in the macula; this 
patient had the first symptoms of night blindness at age 47 
years (Supplementary Figure S3 online). He has a maternal 
uncle affected by typical RP and a clear macular chorioretinal 
dystrophy who has exhibited night blindness since the age of 26 
years. The RCBTB1 duplication was not found in the maternal 
uncle. A duplication encompassing the same exons is present 
in the DECIPHER database (patient identifier: 255256). This 
patient inherited this allele from a healthy parent. A 68.78-kb 
de novo duplication on chromosome 15 was also described for 
this patient. The provided phenotypical features of the patient 
do not point to any retinal dystrophy or other eye disorder.
Sequencing of RCBTB1 in P4 revealed a heterozygous 
missense variant of unknown significance: c.594C>G 
p.(Asp198Glu) (Table 2). The affected uncle was heterozygous 
for the same missense variant.
DIsCUssION
Here, we report a customized oligonucleotide array for copy-
number screening in iRD. More specifically, the arrEYE plat-
form enables identification of CNVs in known iRD genes 
responsible for RP, CRD, and MD, and also in several interest-
ing candidate genes for RP and retina-expressed ncRNAs.
The arrEYE platform uncovered a novel CNV in the HGSNAT 
gene in a patient with RP who was found to be compound 
heterozygous for this CNV and a known missense variant 
c.1843G>A p.(Arg615Thr). HGSNAT mutations have previously 
been associated with MPS IIIC or Sanfilippo syndrome type C, 
an autosomal recessive lysosomal storage disorder caused by 
deficiency of heparan-α-glucosaminide N-acetyltransferase. 
Interestingly, mutations in HGSNAT, one of which was the mis-
sense variant found here, were recently reported in patients 
with nonsyndromic RP.26 The late-onset phenotype described 
here (Figure 2) is entirely in keeping with those reported in that 
study. Transient overexpression of p.(Arg615Thr) in cell lines 
showed a slightly reduced expression of activity (50–80% enzy-
matic activity) compared to the wild type.27,30 The p.(Trp403Cys) 
mutation is often found in cis with p.(Arg615Thr), which signif-
icantly reduces both HGSNAT protein expression and activity.30 
The hypomorphic p.(Arg615Thr) variant in combination with 
a more severe allele might explain the nonsyndromic RP phe-
notype seen here and in the previously reported Dutch family. 
A higher expression of Hgsnat in mouse retina compared with 
other tissues affected in MPS IIIC suggests the need for higher 
HGSNAT activity to maintain proper function of the retina and 
might explain the retinal involvement in the case of more sub-
tle changes in HGSNAT dosage or activity.26 This has also been 
described in other genes associated with multisystem lysosomal 
storage diseases (CLN3 and MFSD8).31,32
The smallest clinically relevant CNV identified in our patient 
cohort was a 1.9-kb single-exon deletion of USH2A that could 
be detected because of the design of consecutive probes cov-
ering the entire gene, including introns. This high-resolution 
probe design, covering intronic regions, also facilitated the 
delineation of CNVs and the establishment of their underly-
ing mechanisms, such as nonallelic homologous recombina-
tion, transposable element insertions, or nonhomologous 
(NH) mechanisms. Little or no homology at the breakpoints 
might indicate a NH mechanism. Nonrecurrent CNVs can be 
caused by various events such as nonhomologous end-joining 
and microhomology-mediated end-joining, or by a template-
switching mechanism during replication.33 No microhomology 
(MH) was found at the breakpoints of the HGSNAT deletion. A 
microinserted sequence (MI) of eight nucleotides at the dele-
tion breakpoints suggests a template-switching mechanism 
(Figure 2e). A copy of the MI was found adjacent (59 bp) to 
the distal breakpoint sequence, corresponding to one of the two 
distances frequently observed between the MI template and the 
breakpoint. It has been suggested that the distance to template 
sites could be related to DNA packing in cells during replica-
tion.33 The presence of MH of two nucleotides shared between 
the proximal and distal sequences surrounding the breakpoints 
of the novel USH2A deletion suggests nonhomologous end-
joining as a MH-mediated repair mechanism (Figure 3d).34
Moreover, a heterozygous duplication involving nine exons 
of RCBTB1 was found in a patient with RP, but not in his 
affected maternal uncle. Haploinsufficiency of RCBTB1 has 
recently been found to be associated with Coats disease (MIM 
300216) and familial exudative vitreoretinopathy (FEVR, 
MIM 133780), both of which are characterized by abnormal 
retinal vascular development. The main clinical features of 
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these congenital vitreoretinopathies are avascularization of 
the peripheral retina and subretinal exudation. Furthermore, 
there is a characteristic range for severity of retinal phenotype, 
from asymptomatic with preserved rod and cone responses to 
a flat ERG due to severe retinal detachment.35 Interestingly, 
our group simultaneously identified RCBTB1 as a disease gene 
for autosomal recessive nonsyndromic and syndromic iRD, 
varying from severe iRD compatible with RP to a progressive 
iRD with central chorioretinal atrophy and peripheral reti-
nal dystrophy. Extraocular features include adult-onset sen-
sorineural hearing loss, lung fibrosis (MIM 178500), thyroid 
involvement (MIM 138800), primary ovarian insufficiency, 
and mild intellectual disability.36 In the family described here, 
an autosomal dominant (with reduced penetrance; see indi-
vidual III:5) or X-linked RP (with an affected female; see II:2) 
is most likely (Supplementary Figure S3b online). The phe-
notype of both the index patient P4 (with the RCBTB1 dupli-
cation and a missense variant) and his maternal uncle (carrier 
of only the RCBTB1 missense variant) does not match with 
the recently described autosomal dominant FEVR phenotype, 
however. Considering the lack of segregation of the duplica-
tion with the RP phenotype in this family, the phenotypic 
presentation, and the occurrence of an overlapping inher-
ited, nonpathogenic duplication in DECIPHER, the RCBTB1 
duplication found here is considered not causal for the RP 
phenotype observed in P4.
A number of methods have been used to identify subtle and 
larger CNVs in iRD, most of which only test coding regions. 
CNV screening based on qPCR or MLPA is restricted to a 
limited number of targets and can result in false-positive sig-
nals (mimicking a deletion) due to single-nucleotide variants 
affecting the primer or probe sequences. A reliable detection 
of small CNVs using NGS data can be challenging in poorly or 
highly variable covered exons. Array CGH is more sensitive to 
detect such small CNVs, particularly with a highly dense and 
evenly distributed set of probes,37 as in the arrEYE platform. 
It is re commended that NGS findings should be confirmed to 
complement CNV analysis in poorly covered regions using 
another technique.12 Genome-wide array CGH with exonic 
probes has been used to confirm WES findings,38 although the 
same shortcomings are envisaged: noncontiguous distribution 
of exons, low-quality probes for GC-rich exons, and no unique 
probes for highly repetitive exons or pseudogenes. An evenly 
spaced probe distribution encompassing both exonic and 
intronic regions can overcome these problems. Although this 
array CGH design facilitates the fine mapping of the breakpoint 
regions, it does not allow for pinpointing exact breakpoint 
regions or differentiating tandem from nontandem duplica-
tions, in contrast to WGS algorithms.39,40
The clinical detection rate of CNVs in iRD genes in our small 
RP cohort is lower than could be expected (2/57; 3.5%). Indeed, 
Khateb et al. showed a higher prevalence (10%) of CNVs in a 
cohort of 60 index cases with arRP and simplex RP.7 With the 
first version of arrEYE, we focused on genes for RP and over-
lapping phenotypes CRD and MD. A next version, however, 
can easily be extended with probes for other iRDs such as Leber 
congenital amaurosis, which could lead to a higher yield.
In conclusion, we designed the first customized array CGH 
platform for high-resolution CNV analysis of the full genomic 
region of known and candidate iRD genes and of retina-
expressed ncRNAs. We identified subtle single-exon to larger 
CNVs in iRD genes that could be characterized at the nucle-
otide level. We report, for the first time, a CNV in HGSNAT 
that, in combination with a missense mutation, leads to arRP, 
thereby further supporting its recently identified role in non-
syndromic iRD. Finally, we expanded the allelic spectrum of 
USH2A and RCBTB1 with novel CNVs. In combination with 
NGS-based approaches, the arrEYE platform can provide an 
integrated molecular diagnosis in iRD.
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